Additional studies focused on trametinib monotherapy are currently underway, including PLGG-MEKTRIC, a large prospective trial comparing daily trametinib monotherapy with weekly vinblastine in children with non-NF1 associated pLGG and without BRAFV600E mutation in France (NCT05180825), and TRAM-01, a phase 2 open-label basket trial in Canada (NCT03363217), is testing trametinib as a single agent in pediatric patients with progressing/refractory glioma or plexiform neurofibroma with MAPK.ERK pathway activation. The gene discussed is NF1; the disease is glioma.